Kinsella Group
Kinsella Group publicly describes itself as a boutique investment bank and business advisory group serving the MedTech sector, with services spanning company sales, recapitalizations, acquisition searches and growth-capital support.
What stands out about Kinsella Group
Kinsella Group focuses on MedTech and medical devices, including contract manufacturing, OEMs, orthopedics, implants, medical plastics and related capabilities. It advises on company sales, recapitalizations and acquisition searches, while certain principals acting through the unaffiliated broker-dealer Burch & Company, Inc. perform specified securities-related services involving capital sourcing and stock- or debt-related M&A transactions.[1][2][4][5][8][9]
What does Kinsella Group do?
Kinsella Group identifies itself as a boutique investment bank and business advisory group serving the MedTech sector. It lists an office at 200 South Wacker Drive, Suite 3100, Chicago, Illinois 60606.[1][2]
Kinsella Group publicly states that it provides MedTech company sales, recapitalizations and acquisition searches for U.S. and international clients. Its public service description also covers buyer and seller advisory and growth-capital or minority-equity support.[1]
Owners comparing advisory firms can also review Auxo’s M&A advisor vs. business broker vs. investment bank comparison, advisor-selection guide, and sell-side advisor evaluation framework.
What should a business owner evaluate before hiring Kinsella Group?
An owner evaluating Kinsella Group can clarify how the firm’s stated mid-sized privately held MedTech focus applies to the owner’s business, how its buyer-informed process would be structured, and whether the proposed assignment would be a company sale, recapitalization or another advisory mandate. The owner should also confirm the applicable securities-services arrangements, engagement fees and expenses, transaction-size expectations, and the specific principals who would lead the work.[1][2][4]
What revenue, EBITDA, enterprise-value or transaction-size ranges are currently preferred for company-sale and M&A engagements
Which growth-capital prerequisites apply, if any, outside the growth-capital service lane
What size transactions and clients does Kinsella Group focus on?
Kinsella Group states that it focuses on MedTech and medical devices, including contract manufacturers, OEMs, orthopedic implants, branded orthopedics, medical plastics manufacturing, medical logistics, healthcare marketing and urology.
Listed manufacturing capabilities include precision machining, metal stamping, forging, grinding, Swiss turning, casting, injection molding, EDM, clean room operations, surface coating, additive manufacturing and electromechanical assembly.[3]
Publicly identified examples include Burke Porter Group’s acquisition of 100% of NACS, Squadron Capital’s acquisition of 70% of the membership interests of Structure Medical, and Tecomet’s acquisition of 100% of the assets of Teleflex’s orthopedic OEM business for 100% cash.
Other examples include Integrated Medical Solutions’ sale of assets and assumption of liabilities to Avalign Technologies for cash at close, Marle Group’s acquisition of a majority interest in Tangible Solutions, and Schivo Medical’s acquisition of Supreme Screw Products. The official Integrated Medical Solutions transaction page states that valuation was undisclosed.[6][7][8][9][10][11]
The firm’s stated transaction services include company sales, recapitalizations and acquisition searches. Its public materials also describe support for negotiated M&A transactions and growth-capital or minority-equity needs.[1]
What does Kinsella Group publicly disclose about fees, process and engagement terms?
The official MedTech services page does not publish a universal minimum revenue, EBITDA, enterprise-value or transaction-size threshold for all engagements. That page also does not state universal engagement-fee percentages, minimum fees, tail periods, termination schedules or expense policies.
The official transaction page for Integrated Medical Solutions’ sale to Avalign Technologies states that valuation was undisclosed. These disclosures leave engagement-specific terms and selected transaction valuations for direct clarification.[1][9]
Kinsella Group states that certain principals are licensed as FINRA securities agents with the unaffiliated registered broker-dealer Burch & Company, Inc. for securities-related services involving capital sourcing and M&A transactions involving stock or debt.[2]
Kinsella Group states that it uses a targeted, research-based acquisition-search approach to generate proprietary deal flow for buy-side clients and uses that buyer-side experience to inform advice to sell-side clients. It also states that acquisition searches can identify non-marketed opportunities through industry knowledge and networks.[1][8]
Questions to ask before hiring Kinsella Group
What revenue, EBITDA, enterprise-value or transaction-size ranges are currently preferred for company-sale and M&A engagements?
Which growth-capital prerequisites apply, if any, outside the growth-capital service lane?
Which recent engagements were sell-side, buy-side or acquisition-search assignments, and what were the closing dates and outcomes?
What services are performed through Burch & Company, Inc., and which services are non-securities advisory services?
What are the engagement fees, success-fee mechanics, minimums, tail provisions, termination rights and expense policies?
Which team members would lead the engagement, and which buyer relationships cover the owner's sector and geography?
Sources & research notes
- Official website / firm overview
- Official website / firm overview
- Industry / market focus
- Geography / market coverage
- Transaction size / criteria
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.